Cytokinetics Announces Proposed Public Offering of Common Stock
23 May 2024 - 6:02AM
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced plans to
offer, subject to market and other conditions, approximately $500
million of shares of its common stock in an underwritten public
offering. There can be no assurance as to whether or when the
offering may be completed, or the actual size or terms of the
offering. Cytokinetics expects to grant the underwriters a 30-day
option to purchase up to an additional 15% of the number of shares
of common stock sold in connection with the offering. All of the
shares of common stock in the offering will be sold by
Cytokinetics.
J.P. Morgan, Goldman Sachs & Co. LLC and
Morgan Stanley are acting as sole joint book-running managers for
the offering.
The securities described above are being offered
by Cytokinetics pursuant to a shelf registration statement
(including a base prospectus) filed on November 18, 2022 with the
Securities and Exchange Commission (SEC), which has become
automatically effective. A preliminary prospectus supplement and
accompanying prospectus relating to the offering will be filed with
the SEC and will be available for free on the SEC's website at
http://www.sec.gov. Copies of the preliminary prospectus supplement
and accompanying prospectus relating to the offering, when
available, may be obtained from: J.P. Morgan Securities LLC,
Attention: Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, New York 11717, by email at prospectus-eq_fi@jpmchase.com
and postsalemanualrequests@broadridge.com; Goldman Sachs & Co.
LLC, Attention: Prospectus Department, 200 West Street, New York,
New York 10282, by telephone at (866) 471-2526, or by email at
Prospectus-ny@ny.email.gs.com; or Morgan Stanley & Co. LLC,
Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New
York, New York 10014, by telephone at 866-718-1649 or by email at
prospectus@morganstanley.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical
company focused on discovering, developing and commercializing
first-in-class muscle activators and next-in-class muscle
inhibitors as potential treatments for debilitating diseases in
which muscle performance is compromised and/or declining.
Forward-Looking Statements
Certain of the statements made in this press
release are forward looking, such as those, among others, relating
to Cytokinetics’ expectations regarding the completion, timing and
size of the proposed offering. Actual results or developments may
differ materially from those projected or implied in these
forward-looking statements. Factors that may cause such a
difference include, without limitation, risks and uncertainties
related to whether or not Cytokinetics will be able to raise
capital through the sale of its securities, the final terms of the
proposed offering, market and other conditions, and the
satisfaction of customary closing conditions related to the
proposed public offering. There can be no assurance that
Cytokinetics will be able to complete the proposed public offering
on the anticipated terms, or at all. You should not place undue
reliance on these forward-looking statements, which apply only as
of the date of this press release. Additional risks and
uncertainties relating to the proposed public offering,
Cytokinetics and its business can be found under the heading “Risk
Factors” in Cytokinetics’ Quarterly Report on Form 10-Q for the
first quarter of 2024, which was filed on May 10, 2024, and other
filings with the SEC, and in the preliminary prospectus supplement
related to the proposed public offering to be filed with the SEC on
or about the date hereof. Except as otherwise required by law,
Cytokinetics does not undertake any obligation to update
forward-looking statements and expressly disclaims any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in its expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are
based.
Contact:CytokineticsDiane WeiserSenior Vice President, Corporate
Affairs(415) 290-7757
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Sep 2023 to Sep 2024